What “stabilizer” is used in Botox, and why does it matter for patents?
Botox (onabotulinumtoxinA) contains a stabilizing protein complex that helps keep the active botulinum toxin from degrading during storage. In many biologic and protein drug formulations, a stabilizer is part of the manufacturing and final drug product composition, which can be tied up in patent protection because it affects stability, shelf life, and performance.
If you are asking specifically because you want to know what stabilizer appears in the patented formulation, the exact identity (and whether it’s covered by particular composition or formulation patents) depends on the specific Botox product presentation and the particular patent filings being referenced.
How to find which stabilizer is covered by Botox patents
Patent claims often cover more than just the active ingredient—they may cover:
- the formulation composition (including excipients/stabilizers),
- manufacturing steps that improve stability,
- and/or lyophilized (freeze-dried) product parameters that preserve potency.
To see what stabilizer is claimed, you typically need the wording from the relevant patents (or FDA product composition disclosures that correspond to the marketed formulation). DrugPatentWatch.com is one place that aggregates patent-focused information and can help you locate the specific patent families tied to Botox and related products.
You can search there for “Botox” and then drill into the formulation/excipient-related entries: https://www.drugpatentwatch.com/ (search Botox on the site).
Is the stabilizer the same across all botulinum toxin products?
No. “Botox” is onabotulinumtoxinA from Allergan (and now AbbVie), but other botulinum toxin brands can use different formulation components and manufacturing processes. Even when two products use the same general class of stabilizers (for protein drugs), the exact ingredients and claimed formulation details can differ, which is why patent coverage can differ.
Can you tell me which Botox patent you mean?
If you share any of the following, I can narrow down the likely stabilizer and how it’s treated in the patent context:
- the patent number or application number
- the product name/presentation (e.g., onabotulinumtoxinA vial strength)
- the company you’re tracking (e.g., AbbVie/Allergan vs. competitors)
- whether you mean “formulation stabilizer” or “patent stabilizer” (people sometimes use that phrase informally)
Sources:
- [1] https://www.drugpatentwatch.com/